Carboplatin hypersensitivity and desensitization in an infant.
Although the reported incidence of carboplatin hypersensitivity is low, it is important to describe it because of its potentially fatal consequences. A 1-year-old Mexican girl weighing 10 kg who had optic nerve glioma was initially scheduled to receive 12 cycles of 600 mg/m2 carboplatin (CBP) as two 300-mg/m2 intravenous infusions administered over 1 hour on 2 different days and a 1-hour intravenous infusion of 1.5 mg/m2 vincristine every 4 weeks. The patient had no history of drug allergies or any type of adverse drug reaction, but she developed itchiness, maculopapular rash, sweating, respiratory distress, and anxiety during the seventh cycle of CBP. According to the algorithm developed by Naranjo et al, the adverse drug reaction was classified as definite secondary to CBP and confirmed by positive skin tests indicating hypersensitivity to the drug. After evaluating the clinical course of the adverse drug reaction and considering the need to continue cancer treatment, a decision was made to desensitize the patient to CBP. The desensitization procedure took 8 hours and was performed during each new chemotherapy cycle until the 12 cycles of chemotherapy were successfully completed. In summary, a case of CBP hypersensitivity in a 1-year-old girl who was successfully desensitized to CBP is reported.
Montiel Herrera
Juan Manuel
JM
Department of Allergy and Pediatric Immunology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico. jmanuelmontiel@hotmail.com
Góngora-Melendez
Marco Antonio
MA
Pineda-Maldonado
Mario Luis
ML
Medina-Sanson
Aurora
A
Del Rio Chivardi
Jaime Mariano
JM
Del Río-Navarro
Blanca Estela
BE
Rosas-Vargas
Miguel Angel
MA
D000707:Anaphylaxis / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D016190:Carboplatin / Q000009:adverse effects* / Q000627:therapeutic use; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000628:therapy*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007223:Infant; D020339:Optic Nerve Glioma / Q000150:complications / Q000188:drug therapy; D019574:Optic Nerve Neoplasms / Q000150:complications / Q000188:drug therapy; D012017:Referral and Consultation; D012882:Skin Tests; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D007073:Immunoglobulin E; D014750:Vincristine; D016190:Carboplatin